Clinical Trial

IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 26, 2024 (before its estimated August 4, 2025 completion). Its status may not reflect the trial's current state.
Summary
IM19 CAR-T cell therapy for IgA nephropathy patients with urinary protein and renal dysfunction, as well as patients with intermediate to high-risk primary membranous nephropathy
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-11-13; most recent amendment 2024-11-25.
Trial Details
NCT Number NCT06690359
Lead Sponsor Beijing Immunochina Medical Science & Technology Co., Ltd.
Conditions IgA Nephropathy, Membranous Nephropathy
Enrollment 12 participants
Start Date 2024-12-13
Primary Completion 2025-08-04 (estimated)
Study Completion 2026-12-20 (estimated)
Updated on ClinicalTrials.gov 2024-11-26